| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/500 - 1/2000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | K18; CK-18; CYK18 |
| Entrez GeneID | 3875 |
| clone | 3G6E4 |
| WB Predicted band size | 48kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human KRT18 (AA: 1-150) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于KRT18抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*"Cytokeratin 18 as a Biomarker in Solid Tumors: Current Applications and Future Perspectives"*
**作者**：Smith J, et al.
**摘要**：该综述总结了KRT18在多种实体瘤(如乳腺癌、结直肠癌)中的表达及其临床意义，重点讨论了KRT18抗体在肿瘤诊断、预后评估及治疗反应监测中的应用，强调其在循环肿瘤细胞检测中的潜力。
2. **文献名称**：*"Antibody-based Detection of Apoptosis-associated Cleavage of Keratin 18 in Liver Disease"*
**作者**：Lee S, et al.
**摘要**：研究利用特异性KRT18抗体检测肝病患者血清中凋亡相关的KRT18片段(如M30抗原)，发现其水平与肝纤维化及炎症程度显著相关，提示其作为非侵入性肝病生物标志物的价值。
3. **文献名称**：*"KRT18 Phosphorylation Status as a Prognostic Marker in Breast Cancer: A Comparative Study Using Phospho-specific Antibodies"*
**作者**：Garcia R, et al.
**摘要**：通过磷酸化特异性KRT18抗体分析乳腺癌组织样本，发现KRT18特定磷酸化位点(如Ser33)的异常激活与肿瘤转移和患者生存率下降相关，为靶向治疗提供潜在靶点。
4. **文献名称**：*"Development of a Novel Monoclonal Antibody Against Human Keratin 18 for Early Detection of Epithelial Damage"*
**作者**：Chen L, et al.
**摘要**：该研究报道了一种新型抗KRT18单克隆抗体的开发，验证其在急性肾损伤和肠道炎症模型中检测上皮细胞损伤的灵敏度和特异性，证明其可用于早期疾病诊断及药物毒性评估。
注：以上文献信息为示例性内容，实际引用需根据具体论文调整。建议通过PubMed或Google Scholar以关键词“KRT18 antibody”、“CK18 biomarker”等检索真实文献。
The keratin 18 (KRT18) antibody is a widely used tool in biomedical research and diagnostics, targeting the KRT18 protein, a type I intermediate filament protein encoded by the *KRT18* gene. As a member of the cytokeratin family, KRT18 pairs with KRT8 to form the cytoskeleton in single-layered epithelial cells, maintaining cellular integrity and mechanical stability. It is prominently expressed in tissues like the liver, pancreas, and gastrointestinal tract.
KRT18 is implicated in various pathological processes. Its cleavage during apoptosis generates soluble fragments (e.g., M30 antigen), serving as biomarkers for cell death in conditions like liver injury, hepatitis, and fibrosis. In cancer research, KRT18 antibodies are employed to study epithelial malignancies (e.g., hepatocellular carcinoma, breast cancer), where altered expression correlates with tumor progression and metastasis. Additionally, KRT18 mutations are linked to cryptogenic cirrhosis and other liver diseases.
Antibodies against KRT18 are utilized in techniques such as immunohistochemistry (IHC), Western blotting (WB), and ELISA to assess tissue-specific expression, disease mechanisms, or therapeutic responses. Clinically, serum KRT18 fragments are measured as non-invasive biomarkers for monitoring liver damage or chemotherapy efficacy. Despite its utility, interpretation requires caution due to cross-reactivity with other keratins and context-dependent expression patterns. Overall, KRT18 antibodies remain vital in unraveling epithelial biology and disease pathogenesis.
×
